Toronto, Ontario and Cambridge, Massachusetts, March 24, 2022 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeutic targets. Accidentally folded protein Toxic oligomers involved in the development of neurodegenerative diseases have been announced today in the next 10.th The annual Neurodegenerative Drug Development Summit will be held March 28-30, 2022 in Boston, Massachusetts.
Dr. Neil Cashman, Chief Scientific Officer of ProMIS, will make an oral presentation on the following titles:Abeta oligomers in Alzheimer’s disease: target involvement and target distraction“, Tuesday, March 29, 2022 at Boston Park Plaza Hotel at 3:00 pm local time.
Much scientific data correlates misfolded oligomers as a toxic molecular species of amyloid beta (Abeta) associated with Alzheimer’s disease. However, using conventional methods, it is difficult to selectively target oligomers while saving other species (including monomers and fibrils) that “distract” the therapeutic antibody from its primary target. Has been proven. Immune recognition of Abeta fibers can also cause dose-limited side effects.Dr. Cashman discusses the use of set coordinates in his presentationTM, Proprietary calculation algorithm. Design constitutive epitopes that specifically target oligomers while protecting monomers and fibrils from immune recognition.
Dr. Cashman’s presentation will be available on the ProMIS website (www.promisneurosciences.com) at the end of the meeting. For more information on the meeting, please visit the organizer’s website.
About ProMIS Neuroscience
ProMIS Neurosciences, Inc. is a neurodegenerative disease, especially Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD). The company’s unique target discovery engine is based on the use of two complementary computational modeling techniques. The company applies molecular dynamics, computational discovery platforms-ProMIS ™ and aggregate coordinates-to predict new targets known as disease-specific epitopes on the molecular surface of misfolded proteins. ProMIS is headquartered in Toronto, Ontario and has an office in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the PMN symbol and on the OTCQB Venture Market under the ARFXF symbol.
For more information, please visit www.promisneurosciences.com and follow us on Twitter and LinkedIn.
For investor information, please contact:
Alpine Equity Advisor
Nicholas Rigopros, President
phone. 617 901-0785
TSX has not reviewed or is responsible for the validity or accuracy of this release. This information release contains information about specific future prospects. Because such information includes known and unknown risks, uncertainties, and other factors whose actual results, performance, or outcomes may differ materially from those described here. These statements should not be read as a guarantee of future performance or results. All forward-looking statements are based on our current beliefs, our assumptions, currently available information, and other factors. Readers are careful not to place undue reliance on these forward-looking statements that are stated only as of the date of this press release. Due to the risks and uncertainties we have stated in our public securities filings, including the risks and uncertainties, actual events may differ materially from current expectations. We disclaim any intention or obligation to update or revise any forward-looking statement as a result of new information, future events, etc.
CBJ News Maker
ProMIS Neurosciences Announces at Canadian Business Journal, 10th Neurodegenerative Drug Development Summit
Source link ProMIS Neurosciences Announces at Canadian Business Journal, 10th Neurodegenerative Drug Development Summit